Changeflow GovPing Pharma & Healthcare Effect of Oral Probiotics on Allergic Rhinitis ...
Routine Notice Added Final

Effect of Oral Probiotics on Allergic Rhinitis Symptoms and Quality of Life

Favicon for changeflow.com ClinicalTrials.gov Studies
Detected
Email

Summary

NIH registered a clinical trial (NCT07532837) examining oral probiotics versus placebo for treating allergic rhinitis symptoms and quality of life. The study will evaluate Lactobacillus rhamnosus F-1 and Lactobacillus reuteri GL-104 in patients with allergic rhinitis, an inflammatory nasal condition affecting sleep, work productivity, and concentration.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH added a clinical trial registration (NCT07532837) for a Phase 2 study investigating the effect of oral probiotics on allergic rhinitis symptoms. The trial will study Lactobacillus rhamnosus F-1 and Lactobacillus reuteri GL-104 versus placebo, measuring quality of life outcomes in patients with allergic rhinitis, an inflammatory condition causing nasal congestion, sneezing, and itchy eyes.

For patients and healthcare providers, this represents an emerging research opportunity for probiotic-based allergy management. The trial registration indicates the study is planned but does not establish treatment protocols or approval status. Those interested should consult ClinicalTrials.gov for recruitment status and eligibility criteria.

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

The Effect of Oral Probiotics on Allergic Rhinitis Symptoms and the Quality of Life

N/A NCT07532837 Kind: NA Apr 16, 2026

Abstract

Allergic rhinitis (AR), also known as nasal allergy, hay fever or seasonal allergic rhinitis, is an inflammatory condition of the nasal passages caused by the immune system's response to allergens in the air. Symptoms include runny or blocked nose, nasal itching, sneezing, and red, itchy, and watery eyes. These symptoms typically occur within minutes of exposure to allergens and can affect sleep, work productivity, and concentration during learning. Many patients with allergic rhinitis also suffer from conditions such as asthma, allergic conjunctivitis, or atopic dermatitis.Symptoms in the majority of patients tend to recur and persist over time. While medication can alleviate the symptoms, complete cure is challenging to achieve.

Probiotics are generally defined as microorganisms that, when ingested, provide beneficial effects to the host. They primarily consist of bacteria that produce lactic acid, including Lactobacilli, Bifidobacteria, and Saccharomyces boulardii. One known mechanism underlying allergic diseases is the overactivation of Th2 cells, leading to an imbalance in the Th1/Th2 ratio. Previous research has explored whether the use of probiotics can prevent allergic diseases. Numbers of studies indicate that probiotics have the ability to modulate the immune system by increasing anti-inflammatory cytokines such as IFN-γ, IL-10, and IL-12 to enhance Th1 cell activity. Simultaneously, they suppress pro-inflammatory cytokines like IL-4, IL-5, and IL-13, inhibiting...

Conditions: Allergic Rhinitis

Interventions: Lactobacillus rhamnosus F-1, Lactobacillus rhamnosus F-1、Lactobacillus reuteri GL-104, Placebo

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07532837

Who this affects

Applies to
Patients Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Immunology research Probiotic intervention study
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!